JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies

Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.

Zacks Investment Research • Jun 18, 2026

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop ​T-cell engaging multispecific antibodies for cancer, the ‌companies said on Wednesday.

Reuters • Jun 17, 2026

Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.

Benzinga • Jun 17, 2026

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaningful changes in cardiometabolic risk markers following Xywav initiation For U.S. media and investors only DUBLIN, June 16, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic impacts of reduced sodium exposure in patients living with these debilitating conditions.

PRNewsWire • Jun 16, 2026

JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study

Jazz Pharmaceuticals' Zepzelca fails a phase III lung cancer study, but strong first-line uptake and 2026 guidance remain unchanged.

Zacks Investment Research • Jun 15, 2026

Jazz Pharmaceuticals lung cancer drug fails main trial goal

Jazz Pharmaceuticals said on Friday its lung cancer drug Zepzelca ​failed to meet the main goal of ‌improving overall survival in a late-stage study, potentially risking its current regulatory status.

Reuters • Jun 12, 2026

Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer

For U.S. media and investors only DUBLIN, June 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 LAGOON trial, conducted by PharmaMar, evaluating Zepzelca® (lurbinectedin) in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC). The trial did not meet its primary endpoint of overall survival (OS) evaluating Zepzelca as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan.

PRNewsWire • Jun 12, 2026

Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jun 11, 2026

Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst

Jazz Pharmaceuticals PLC's (NASDAQ:JAZZ) revenue growth and stock valuation is being driven by the adoption of Ziihera as a first-line (1L) treatment of HER2-positive (HER2+) metastatic gastroesophageal adenocarcinoma (GEA), according to BofA Securities.

Benzinga • Jun 10, 2026

Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 4, 2026